entertainment -WSS

entertainment

author：comprehensive 2025-10-01 18:45:05 - browse：69

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Public health communication lessons from Covid

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

As the dark side of IVF slowly comes into focus, even more transparency is needed

Hospitals, health systems can help patients avoid medical debt

Hospitals, health systems can help patients avoid medical debt

There's an unseen cost to disruptive road

To bolster infectious disease surveillance, genomics powerhouses team up

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pumping milk in bathrooms at health conferences is common

Hollywood unions extend contract negotiations for actors

Stoke drug shows lower activity against childhood epilepsy

Medicare details structure of new drug price negotiation program

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

New air purifier tech could be key to improving indoor air quality

High breast density mammograms need follow

focus

The mammogram wars are not over

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Printout prescription drug information shouldn’t go digital

Inaction leaves children at risk from dangerous chemotherapy drug

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Alexander Hamilton and the argument for universal insurance

Wikipedia

hotspot

knowledge

hotspot